NervGen Pharma (TSE:NGEN) has released an update.
NervGen Pharma Corp., a biotech firm focusing on treatments for nervous system damage, has issued 950,000 stock options to its directors and consultants. These options are priced at $1.79, with varying vesting periods and exercisable for up to ten years, in alignment with TSX Venture Exchange policies and the company’s own stock option plan.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
